

SSAI ANNUAL CONGRESS AND SWISS AUTOIMMUNE LIVER DISEASE MEETING

27 - 28 AUGUST, 2026 · PALAZZO DEI CONGRESSI LUGANO

SSAI Société Suisse d'Allergologie et d'Immunologie
Schweizerische Gesellschaft für Allergologie und Immunologie
Swiss Society for Allergology and Immunology

**Fondazione
Epatocentro Ticino**

CREDITS

	SSAI	SGDV/ SSDV	SGG/ SSG	FAMH	SGR/ SSR	SGPath/ SSPath	SSM0/ SGM0/SSOM	SGInf	SGP/ SSP	SGAIM
27 August	8	5	7	6	7	6	6	1	1	4
28 August	6	5	3	6	5	5	6	1	1	3
Total	14	10	10	12	12	11	12	2	2	7

CONGRESS ORGANISATION

Medworld AG,
Sennweidstrasse 46, 6312 Steinhausen
Phone: +41 41 748 23 00,
registration@medworld.ch

Further credits will be
announced on the website

ssai-swissaild-congress.ch



ENDORSED BY:



Swiss Association for
the Study of the Liver



WELCOME FROM THE PRESIDENTS OF THE ORGANISING COMMITTEE

Dear Friends and Colleagues,

We are delighted to invite you to the **SSAI Annual Congress and the Swiss Autoimmune Liver Disease Meeting, a joint event of the Swiss Society for Allergology and Immunology (SSAI) and the Fondazione Epatocentro Ticino.**

It will take place on **27 - 28 August 2026**, at the beautiful Palazzo dei Congressi in Lugano. While maintaining the typical SSAI diversity, this collaboration reflects a growing convergence between immunology and hepatology, and is an opportunity for translational communication and research. By joining forces, we aim to foster scientific excellence, promote innovation, and create a dynamic space for interdisciplinary and professional development.

The congress is designed for a broad yet specialized audience, bringing together clinicians, researchers, and participants from the industry from Switzerland and abroad. Participants will include experts from various fields, such as clinical to basic allergology and immunology, as well as laboratory diagnostics. In addition, hepatologists and liver disease specialists will find a platform for cutting-edge insights and collaborative exploration.

Renowned speakers will share their expertise across a range of topics, offering new perspectives on understanding, diagnosis and treatment of immunological and liver-related diseases. Beyond the scientific sessions, attendees will have the chance to engage in scientific discussions, discover novel research during the poster sessions, and network with colleagues on the shores of Lake Lugano.

We look forward to your participation in making this event a truly memorable and rewarding experience. Together with the organising committee, we are excited to welcome you to Lugano for what promises to be an inspiring and dynamic gathering of minds.

With our warmest regards,

Presidents of the Organising Committee



**Prof. Dr.
Greta Guarda**

Group Leader, Institute for Research in Biomedicine and Vice-Dean Research Faculty of Biomedical Sciences, Università della Svizzera italiana (USI)



**Prof. Dr. med.
Andreas Cerny**

Director, Fondazione Epatocentro Ticino Clinica Luganese Moncucco, Internal Medicine

SCIENTIFIC ADVISORY COMMITTEE SSAI



**PD Dr. med.
Marcel Bergman**
Ente Ospedaliero Cantonale
(EOC) / Università della
Svizzera italiana (USI)
Bellinzona / Lugano



**Dr.
Luca Bernasconi**
Kantonsspital Aarau
Aarau



**Prof. Dr. med.
Andreas Bircher**
Universitätsspital Basel
Basel



**Prof. Dr.
Arianna Calcinotto**
Institute of Oncology
Research (IOR) /
Università della Svizzera
Italiana (USI)
Bellinzona / Lugano



**Dr. med.
Massimiliano Fontana**
Ente Ospedaliero
Cantonale (EOC)
Mendrisio




**Prof. Dr.
Roger Geiger**
Institute for Research
in Biomedicine (IRB) /
Università della Svizzera
italiana (USI)
Bellinzona / Lugano



**Dr. med.
Gaia Mancuso**
Ente Ospedaliero
Cantonale (EOC)
Bellinzona



**Prof. Dr.
Samuel P. Nobs**
Institute for Research
in Biomedicine (IRB) /
Università della Svizzera
italiana (USI)
Bellinzona / Lugano



Alessia Palumbo
Ente Ospedaliero
Cantonale (EOC)
Bellinzona



**Prof. Dr. med.
Davide Robbiani**
Institute for Research
in Biomedicine (IRB) /
Università della Svizzera
italiana (USI)
Bellinzona / Lugano



**Prof. Dr.
Federica Sallusto**
Institute for Research
in Biomedicine (IRB) /
Università della Svizzera
italiana (USI) / and ETH
Zurich (ETHZ)
Bellinzona / Lugano /
Zürich

SCIENTIFIC ADVISORY COMMITTEE AILD



Carina Bobzin
Swiss HePa – Swiss liver
patients association
Zollikerberg



**Prof. Dr. med.
Magdalena Filipowicz**
Kantonsspital Baselland
Liestal



**Prof. Dr. med.
Michael Heneghan**
King's College Hospital
London UK




**Dr. med.
Mirjam Kolev**
Inselspital Bern
Bern



**Prof. Dr. med.
Andreas Kremer**
Universitätsspital Zürich
Zürich



**Dr. med.
Giulia Magini**
Geneva University
Hospitals (HUG)
Genève



**Prof. Dr. med.
Giorgina Mieli-Vergani**
King's College Hospital
London UK



**PD Dr. med.
Christiane Sokollik**
Inselspital – Children's
Hospital Bern
Bern



**PD Dr. med.
Benedetta Terziroli
Beretta-Piccoli**
Ente Ospedaliero Cantonale
(EOC)
Lugano



**Prof. Dr. med.
Diego Vergani**
King's College Hospital
London UK

PROGRAMME OVERVIEW – THURSDAY, 27 AUGUST 2026

	Sala A	Sala B1	Sala B2	Sala B3	Sala C	Sala E	
09:00	Registration						
09:15							
09:30							
09:45							
10:00	Welcome						
10:15	B Cells in Autoimmunity						
10:30							
10:45							
11:00	Coffee						
11:15							
11:30							
11:45							
12:00	T Cells in Tolerance and Immunity						
12:15							
12:30	Lunch						
12:45							
13:00							
13:15							
13:30		Industry Symposium	Guided Poster Tour I	Industry Symposium	Industry Symposium		
13:45							
14:00		Clinical Immunology		New Levels of Immune Regulation	Acteria Awardees Session on Immunology and Allergy	Granulomatous Disease: Focus on Sarcoidosis	
14:15							
14:30							
14:45							
15:00							
15:15							
15:30	Coffee / Scientific Industry Talk						
15:45							
16:00							
16:15							
16:30		Hot Topics Autoimmune Liver Disease		Allergology and Clinical Immunology I	Innate immunity, inflammation, and more	T cells and antitumor responses	
16:45							
17:00							
17:15							
17:30	Room Change						
17:45							
18:00							
18:15							
18:30		AILD Research Oral presentations on Autoimmune Liver Disease Research projects		SSAI General Assembly		AILD Patients' Session	
18:45							
19:00							
19:15	Congress Dinner: Splendide Royale						
from 19:30							

Colour legend:

Parallel Session	Industry Symposia	Plenary Lecture	SSAI-AILD Session
Short Communication	Poster	AILD Session	General Assembly

PROGRAMME OVERVIEW – FRIDAY, 28 AUGUST 2026

	Sala A	Sala B1	Sala B2	Sala B3	Sala C	Sala E
08:30	Registration					
08:45						
09:00						
09:15						
09:30	Allergology and Clinical Immunology II	Hot Topics Autoimmune Liver Disease		Autoimmunity, inflammatory diseases, and more	Infection, computational analyses, and more	SYIS Session
09:45						
10:00						
10:15						
10:30	Coffee					
10:45						
11:00						
11:15						
11:30		Cancer and Immunity		Drug Related Immunological Reactions	Clinical Allergology	Diagnostic
11:45						
12:00						
12:15						
12:30	Lunch					
12:45						
13:00						
13:15						
13:30		Industry Symposium	Guided Poster Tour II	Industry Symposium		
13:45	Award Ceremony					
14:00	Senescence and Immunity: Autoimmunity in the Elderly and Immune Dysfunction					
14:15						
14:30						
14:45						
15:00						
15:15						
15:30	Clinically Relevant Primary Immune Deficiencies (PID): What Is New?					
15:45						
16:00						
16:15	Closing Ceremony					
16:30						

Colour legend:

Parallel Session	Industry Symposia	Plenary Lecture	SSAI-AILD Session
Short Communication	Poster	AILD Session	

Available soon
Now approved



Rhapsido®
(remibrutinib)

WHEN CSU QUIETS DOWN, EVERYDAY
LIFE COMES BACK INTO FOCUS^{°,§,1,2}

Imaginary patient.

RHAPSIDO® (remibrutinib) – a new oral add-on therapy option for adult CSU patients who are still symptomatic despite H₁ antihistamines.³

Meaningful symptom relief for ~ 9 out of 10 patients^{#,2}



Fast and sustained improvement in disease activity^{§,1,4}



Favorable safety profile^{*,3,4}



REMIX-1/-2 are identical, randomised, double-blind, placebo-controlled phase III studies to investigate the efficacy and safety of RHAPSIDO® in adults with symptomatic CSU despite H₁ AHS. Patients were randomised 2:1 to receive either RHAPSIDO® 25 mg twice daily (n = 613) or placebo (n = 312) for 24 weeks, each in addition to H₁ AHS. This was followed by a 28-week open-label phase where the placebo group was switched to RHAPSIDO®. The primary endpoint was the change in the UAS7 from baseline to Week 12.¹

° “CSU quiets down” refers to the reduction in symptoms in CSU patients measured as a clinically relevant improvement in the UAS7 in Week 12 versus baseline. RHAPSIDO® was found to have more marked average improvements than placebo: REMIX-1: -20.0 ± 0.7 vs. -13.8 ± 1.0; REMIX-2: -19.4 ± 0.7 vs. -11.7 ± 0.9; p < 0.001.¹

§ “Everyday life comes back into focus” refers to an exploratory analysis of pooled data from REMIX-1/-2 on sleep and activity interference in CSU patients, measured with the SIS7 and AIS7 over 7 days. From baseline to Week 24, RHAPSIDO® was found to have more marked average improvements than placebo: SIS7: -9.3 ± 6.0 vs. -7.1 ± 6.3; AIS7: -9.5 ± 5.9 vs. -7.4 ± 6.0. The analysis was not designed to assess statistical significance.²

“Meaningful symptom relief” refers to an exploratory analysis of pooled data from REMIX-1/-2 on the proportion of CSU patients who achieved a meaningful symptom relief at any time from baseline to Week 12, defined as an MWPC in the UAS7 of -10.5 points versus baseline. This was achieved by 87.1% of patients receiving RHAPSIDO® versus 69.6% of patients receiving placebo. The analysis was not designed to assess statistical significance.²

§ Improvements in the UAS7 were sustained over 52 weeks, as shown by an exploratory and descriptive analysis of REMIX-1/-2. The analysis was not designed to assess statistical significance.⁴

* Adverse drug reactions with an incidence of ≥ 3% were upper respiratory tract infections, haemorrhage, headache, and nausea. In the placebo-controlled phase III studies, adverse drug reactions were primarily mild to moderate in severity.³ The safety profile of RHAPSIDO® in patients treated for up to 52 weeks was the same as in the 24-week treatment phase.⁴ Further information on warnings and precautions can be found in the Swiss information for healthcare professionals.³

AH: antihistamines. AIS7: activity interference score over 7 days. CSU: chronic spontaneous urticaria. MWPC: meaningful within-patient change. SIS7: sleep interference score over 7 days. UAS7: urticaria activity score over 7 days.

1. Metz M, et al. Remibrutinib in Chronic Spontaneous Urticaria. N Engl J Med. 2025;392(10):984-994.

2. Mosnaim G, et al. Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2. Ann Allergy Asthma Immunol. 2026:S1081-1206(26)00271-1. Epub ahead of print.

3. RHAPSIDO® (remibrutinib) Swiss information for healthcare professionals: www.swissmedicinfo-pro.ch

4. Giménez Arnau AM, et al. Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies, J Allergy Clin Immunol. 2026;157(1):143-154.

Novartis provides the listed references upon request.

RHAPSIDO® (remibrutinib) is indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult patients who are still symptomatic despite H₁ antihistamine therapy.³

▼ This medicinal product is subject to additional monitoring. For more information, see the healthcare professional information/patient information for RHAPSIDO® at www.swissmedicinfo-pro.ch.

Novartis Pharma Schweiz AG, Suurstoffi 14, 6343 Rotkreuz, Switzerland; Tel. +41(0)41 763 71 11, www.novartispharma.ch



FA-11733712; 07/2026



RHAPSIDO®
(remibrutinib)

Abridged prescribing
information
Dispensing category: B

PROGRAMME – THURSDAY, 27 AUGUST 2026

09:00 - 09:45

Registration

09:45 - 10:00

Wellcome to the Joint Meeting of SSAI and SASL – AILD

Sala A

Greta Guarda, Bellinzona; Andreas Cerny; Giovanni Pedrazzini, Lugano

10:00 - 11:00

Plenary 1 – B Cells in Autoimmunity

Sala A

Davide Robbiani, Bellinzona; David Semela, St. Gallen

Antibody-selective treatment in autoimmunity

Harald Prüss, Berlin DE

B cells across cancer and autoimmunity

Claudia Mauri, London GB

11:00 - 11:30

Coffee break

11:30 - 12:30

Plenary 2 – T Cells in Tolerance and Immunity

Sala A

Magdalena Filipowicz, Basel; Christoph Hess, Basel

Checkpoint Inhibitor–Induced Hepatotoxicity: Diagnosis and Management

Eleonora de Martin, Villejuif FR

T cells: From Immune Tolerance to Autoimmunity

Federica Sallusto, Bellinzona

12:30 - 14:00

Lunch Break

12:45 - 14:00

Guided poster tour I

Sala B2

Arianna Calcinotto, Bellinzona/Lugano; Davide Robbiani, Bellinzona/Lugano; Johannes Trück, Zürich; Marcel Bergmann, Bellinzona/Lugano

TS01 Targeted discovery of natural NY-ESO-1-specific T-cell receptors from long-term cancer survivors for efficient and safe TCR-T cell therapy

Quentin Gibaut, Epalinges

TS05 Lactate and TGFβ1 Reprogram NK Cells Toward a Tissue-Resident, Low-Cytotoxic Phenotype in Idiopathic Inflammatory Myopathies

Thao Tran, Genève

A05 Engineered allergen-specific regulatory T cells suppress birch pollen–induced airway inflammation

Ana Alcaraz-Serna, Lausanne

A02 Uncovering chlorhexidine allergy in perioperative anaphylaxis

Maria Melo, Porto PT

A03 Automated Skin Prick Test Reading: Diagnostic Accuracy and Time Efficiency Compared with Manual Assessment

Elnaz Arjmand, Bern

A01 Dupilumab/ anti-IL-4R alpha modulates Inflammatory Macrophage Memory in T2-high Asthma

Isika Ram, Epalinges

5

> ssai-swissaild-congress.ch

SESSIONE PER I PAZIENTI

SSAI ANNUAL CONGRESS AND SWISS AUTOIMMUNE LIVER DISEASE MEETING

PATIENTS' SESSION

GIOVEDÌ 27 AGOSTO 2026 · PALAZZO DEI CONGRESSI LUGANO · DALLE 17:45 · SALA E

SSAI Société Suisse d'Allergologie et d'Immunologie
Schweizerische Gesellschaft für Allergologie und Immunologie
Swiss Society for Allergy and Immunology

**Fondazione
Epatocentro Ticino**

Cari pazienti, cari familiari, amici e tutti gli interessati,

Siamo lieti di invitarvi alla **Sessione per i Pazienti** del **Congresso Svizzero delle Malattie Autoimmuni del Fegato 2026** e del Congresso Annuale SSAI.

La sessione è dedicata alle persone affette da malattie autoimmuni del fegato, nonché ai loro familiari e accompagnatori. I medici presenteranno brevemente alcuni dei principali aspetti e delle sfide quotidiane che i pazienti devono affrontare, fornendo spiegazioni chiare e accessibili sui temi più rilevanti.

Il focus principale della sessione sarà una discussione aperta e interattiva, che offrirà ai pazienti la possibilità di porre liberamente domande e approfondire i diversi aspetti della malattia.

Nota: la partecipazione dei pazienti è limitata esclusivamente a questa sessione. In conformità con il Codice Pharma e i requisiti di Ethical MedTech, l'accesso è consentito unicamente alla sala della sessione. Purtroppo non è possibile accedere all'area espositiva.

Siamo lieti di darvi il benvenuto a Lugano per questa sessione speciale.

Cordiali saluti
Il Comitato Organizzatore

Prof. Dr. med. Andreas Cerny
Director, Fondazione Epatocentro Ticino /
Clinica Luganese Moncucco, Internal Medicine

Prof. Dr. Greta Guarda
Group Leader, Institute for Research in Biomedicine
and Vice-Dean Research / Faculty of Biomedical
Sciences, Università della Svizzera italiana (USI)

Malattie autoimmuni del fegato: gli esperti rispondono

Relatore:



**Dr. med.
Massimiliano Fontana**
Ospedale Regionale di
Mendrisio, Beata Vergine



Antonio Galante
Fondazione
Epatocentro Ticino,
Lugano



Mariangela Luzzi
PERSONALITYLAB,
Melide

Rappresentanti associazione pazienti:



Claudia Rizzi
SwissHepa,
Lugano



Sandro Rusconi
University of Fribourg,
Switzerland, Member
of the Board of
Malattie Genetiche
Rare



Davide Salvioni
AMAF Associazione
malattie autoimmuni
del fegato
Muggio-Como

Moderatore:



Prof. Andreas Cerny
Director, Fondazione
Epatocentro Ticino /
Clinica Luganese
Moncucco, Internal
Medicine

Sponsor:



Con l'appoggio di:

PROGRAMME – THURSDAY, 27 AUGUST 2026

13:00 - 13:45 Industry Symposium

Sala C

**Anaphylaxis Today:
From Patient Pathways to Clinical Practice**
Giovanni Ferrari, Lugano

Giovanni Ferrari, Lugano;
Kathrin Scherer Hofmeier, Basel



Sala B1

**Improving Disease Control in HAE:
New Mechanisms and Perspectives**
Christina Weber, Zürich

**Understanding HAE: From Bradykinin Biology to
Clinical Disease Control**
Peter Jandus, Genève



**The Evolving HAE Treatment Landscape:
Practical Strategies to Improve Disease Control**
Christina Weber, Zürich

Sala B3

Personalising PBC Care in Daily Practice

Magdalena Filipowicz, Basel; Andreas Kremer, Zürich;
David Semela, St. Gallen



14:00 - 15:30

SSAI-AILD Parallel Session

Sala E

Granulomatous Disease: Focus on Sarcoidosis

Andreas Cerny, Lugano; Massimiliano Fontana, Mendrisio

Sarcoidosis: From a Pneumological Perspective

Katrin Hostettler Haack, Basel

Sarcoidosis: hepatological insights

Nasser Semmo, Bern

Sarcoidosis as a systemic disease – pitfalls and mimickers

Peter Korsten, Sendenhorst DE

**Pathophysiology and actual treatment concepts in Macrophage
activation syndrome / HLH**

Klaus Tenbrock, Bern

Sala C

Acteria Awardees Session on Immunology and Allergy

Anne Hosmalin, Paris FR; Federica Sallusto, Bellinzona

**How Prior Immune Experiences Shape Long-Term Tissue Immunity:
From Skin Infection to Allergic Asthma**

Mariem Radhouani, Gent BE

**T Cell Immune Regulation in the Liver and Beyond:
From Dysfunction to Hormonal Imprinting**

Valentina Venzin, Paris FR

How translational research can shape allergy management

Alexander Eggel, Bern

PROGRAMME – THURSDAY, 27 AUGUST 2026

Sala B1	Clinical Immunology Antonio Galante, Lugano; Mike Recher, Basel ANCA-associated vasculitis: from autoantibodies to targeted treatments Thomas Hauser, Zürich Systemic lupus erythematosus: the role of B cells in pathogenesis and treatment Camillo Ribi, Lausanne IgG4-Related Disease: Pathophysiology, Diagnosis and Treatment Jörg Seebach, Genève
Sala B3	New Levels of Immune Regulation Mirjam Kolev, Bern; Samuel P. Nobs, Lugano Beyond pathogenicity: Population genomics reveals an unexpected gene-phenotype relationship Christoph Hess, Basel Mast cells as orchestrators of skin inflammation Anne Dudeck, Magdeburg DE The role of trained immunity in inflammation and cancer Triantafyllos Chavakis, Dresden DE
15:30 – 16:00	Coffee break in the Industry Exhibition
15:35 – 15:55	Scientific Industry Talk Beckman Coulter Life Sciences; Booth Nr. 01 A New Streamlined Basophil Activation Testing Platform to Facilitate Translational Allergy Research and Multicenter Clinical Trials Jean-Marc Busnel, Marseille FR
16:00 – 17:30	Hot Topics
Sala B1	Hot Topic 1: Autoimmune Liver Disease Christine Bernsmeier, Basel; Antonio Galante, Lugano Liver Malignancy Risk in Autoimmune Liver Diseases: Pathogenesis and Clinical Implications Michael Heneghan, London GB Variant Syndromes in 2026: New Insights and Evolving Concepts Vincenzo Ronca, Milano IT IgG4-Related Disease: From Diagnostic Dilemmas to Emerging Opportunities Yoh Zen, London GB Clinical management and surveillance in daily practice in PSC Ulrich Beuers, Amsterdam NL

PROGRAMME – THURSDAY, 27 AUGUST 2026

16:00 – 17:30	Short Communication Sessions
Sala E	T cells and antitumor responses Grégory Verdeil, Lausanne; Sebastian Wildi, Bern SC01 Tumor Cell-Intrinsic PDGFRB Drives BC Progression and Immune Remodelling Hajar El Ahanidi, Genève SC02 The Development of a Novel 3D Model for Studying Immune Cell Motility and Tumour Interactions in Immunotherapy Testing James Adams, Bellinzona SC03 Colorectal cancer-infiltrating bacteria promote the proliferation of CD4-CD8- Vδ2+ γδ T cells endowed with antitumor properties Martina Villa, Bellinzona SC04 DNA damage responses induced by dysfunctional mitochondria orchestrate commitment of T cell exhaustion Kung-Chi Kao, Epalinges SC05 Investigating the role of the IL-4/STAT6 axis on exhausted CD8 T cell development and immunotherapy responses Morgan Le Gall, Basel SC06 Divergent contribution of CDK4 and CDK6 on tailoring mitochondrial fitness and T cell function in the tumor microenvironment Karina Hajdu, Lausanne SC07 Understanding the mechanisms underlying the pro-tumoral effects of PD-1 in T cells Irene Buzzago, Bellinzona SC08 Kupffer cell-mediated intrahepatic T cell priming diversifies T cell differentiation and anti-tumor immunity in hepatocellular carcinomas Jaeoh Park, Epalinges
Sala C	Innate immunity, inflammation, and more Ales Drobek, Epalinges; Greta Guarda, Bellinzona SC09 CD39 defines a cytotoxic tumor-associated NK cell state responsive to NKG2A blockade in lung cancer Karin Schauble, Basel SC10 Gut microbiota shape humoral responses to mRNA vaccines through metabolic remodeling Giandomenica Iezzi, Bellinzona SC11 Novel bone materials selectively modulate the human immune response to favor remodeling over acute inflammation Huseyn Babayev, Davos Wolfgang

COPD

SEA

CRSwNP

There's something
NUCALA about them

EGPA

HES

APPROVED FOR
FIVE EOSINOPHILIC
DISEASES*

NUCALA
mepolizumab

These fictional patient images are for illustration purposes only.

Abbreviations: COPD: Chronic Obstructive Pulmonary Disease; CRSwNP: Chronic Rhinosinusitis with Nasal Polyps; EGPA: Eosinophilic Granulomatosis with Polyangiitis; HES: Hypereosinophilic Syndrome; SEA: Severe Eosinophilic Asthma.

References: 1. Nucala product information 12/2025. www.swissmedicinfo-pro.ch (accessed in May 2026).

For detailed information, please visit www.swissmedicinfo-pro.ch.

Please report adverse drug reactions to pv.swiss@gsk.com.

Trademarks are owned by or licensed to the GSK group of companies.

© 2026 GSK group of companies or its licensor. GlaxoSmithKline AG, Neuhoferstrasse 4, 6340 Baar

PM-CH-MPL-JRNA-250003-05/2026

- SC12 Large Immune Complexes Suppress Influenza Vaccine Responses via the Inhibitory Fc-Gamma Receptor IIb on Dendritic Cells
Viacheslav Bolotnikov, Bellinzona
- SC13 Maltol and ethyl maltol disrupt epithelial barrier integrity and induce oxidative stress in human nasal organoids
Bingjie Zhao, Davos Wolfgang
- SC14 Clusters of GSDMD and GSDME mediate neutrophil pyroptosis in Cryopyrin Associated Periodic Syndrome (CAPS)
Zhehao Tan, Bern
- SC15 Intratumoral microbiota and host genotype cooperatively shape neutrophil cytotoxic functions in colorectal cancer
Elisa Sorrenti, Bellinzona
- SC16 Lymph node spatial organization of B cell lymphoma modulates NK cell immunosurveillance through IL-1α
Kamil Chahine, Bellinzona

Sala B3

Allergology and Clinical Immunology I

Marcel Bergman, Bellinzona; Fabio Simon Ryser, Bern

- SC17 Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks: Results from the Phase 3 KONFIDENT Trial
Mauro Cancian, Padova IT
- SC18 Efficacy and safety of intralymphatic immunotherapy with grass allergoid and microcrystalline tyrosine: a double-blind randomised placebo-controlled trial
Lara Šošić, Zürich
- SC19 Safety and immunogenicity of heterologous RSV revaccination with mRNA-1345 after primary vaccination with protein-based vaccine
Daphne McCarthy, Basel
- SC20 Taste Aversion and Adverse Events Equally Drive Oral Immunotherapy Discontinuation: A Real-World Multi-Allergen Analysis in Pediatric Patients
Johannes Trück, Zürich
- SC21 A humanised plant lectin-antibody fusion as a broad-spectrum therapeutic against emerging respiratory viruses
Louis Renner, Bellinzona
- SC22 Heat-treated egg allergens show lower basophil activation: A path toward safer oral immunotherapy
Marta Paolucci, Zürich
- SC23 Subclinical inflammatory endotypes within healthy individuals
Ismail Ogulur, Davos Wolfgang
- SC24 Predicting Outcomes of Peanut Oral Food Challenge: A Paediatric Cohort Analysis
Johannes Trück, Zürich

CONGRESS DINNER

Splendide Royale

You are warmly invited to the Congress Dinner 2026 in Lugano — an evening of celebration, inspiration, and meaningful connections.

The event will take place at the Hotel Splendide Royal Lugano, beautifully located on the shores of Lake Lugano. With its historic charm, refined atmosphere, and breathtaking lake views, the Splendide provides the perfect setting for an unforgettable congress evening.

We look forward to sharing an enjoyable evening with you in Lugano.

Schedule

19:30 h
Congress Dinner at the «Hotel Splendide Royal Lugano»

Costs

CHF 130 per person

Location

Hotel Splendide Royal Lugano, Riva Antonio Caccia 7, 6900 Lugano



17:30 - 17:45

Room change

17:45 - 19:15

Sala B1

AILD Research Session

AR01 A single-cell atlas of checkpoint inhibitor-induced liver injury links shared liver-tumour CD8+ T cell clones to cytotoxicity and macrophage crosstalk
Sarp Uzun, Basel

AR02 Induced regulatory T cells from patients with primary biliary cholangitis are suppressive and stable and are different from natural regulatory T cells
Irene Lasa Elozegi, Milano IT

AR03 Seladelpar Linked to Sustained Reduction in Cholestatic Markers and Consistent Safety Profile in Primary Biliary Cholangitis up to 48 Months in ASSURE
Andreas Kremer, Zürich

AR04 Targeting auto(mito)phagy rescues mitochondrial function and prevents aberrant immune activation in experimental models of primary biliary cholangitis
Irene Lasa Elozegi, Milano IT

AR05 Standardized Body Mapping Reveals Distinct Topographical Patterns of Hepatobiliary Pruritus
Andreas Kremer, Zürich

AR06 The immunoproteasome as a target in autoimmune hepatitis
Michael Basler, Kreuzlingen

AR07 Liver Transplantation for Autoimmune Hepatitis: A Comprehensive 35 Year Single-Center Experience
Reghan Conrey, Los Angeles US

AR08 B-cell activation signatures are independently associated with adverse clinical outcomes in primary biliary cholangitis
Mirjam Kolev, Bern

17:45 - 19:00

Sala E

SESSIONE PER I PAZIENTI

Andreas Cerny, Lugano

Malattie autoimmuni del fegato: gli esperti rispondono

Massimiliano Fontana, Mendrisio; Antonio Galante, Lugano; Mariangela Luzzi, Melide

Rappresentanti associazione pazienti

Claudia Rizzi, Lugano; Sandro Rusconi, Fribourg; Davide Salvioni, Muggiò-Como

17:45 - 18:45

Sala B3

SSAI General Assembly

From 19:30

Congress Dinner at the «Splendide Royale»

PROGRAMME – FRIDAY, 28 AUGUST 2026

Sala C	Infection, computational analyses, and more Ping-Chih Ho, Epalinges; Karin Schäuble, Basel
	SC33 Human antibodies against West Nile and related orthoflaviviruses Tomas Cervantes Rincon, Bellinzona
	SC34 Tissue-resident memory CD8+ T cells use mechanosensing for local immunesurveillance Aditya Seth, Fribourg
	SC35 Balanced Immune Reprogramming by Virtual Infection: Simultaneous Enhancement of Activation, Regulation, and Trafficking Markers Georgia Papadopoulou, Genève
	SC36 MIC1: motility-based immune cell identifier Giuseppe Ricciardi, Bellinzona
	SC37 Phospholipid regulation of CD8+ T cell-dendritic cell interaction duration Alex Boficudros, Fribourg
	SC38 Regulatory factor X 7 limits Myc activity during B cell activation and suppresses Myc-dependent lymphomagenesis Jessica Guerra, Bellinzona
	SC39 Immunodominance of the HLA class I restricted response to SARS-CoV-2 vaccine revealed by two unbiased screening approaches Cecilia Adragna, Bellinzona
	SC40 ArhGAP15 controls memory generation in CD8+ T cells Elissa Khachan Hajj, Fribourg
Sala A	Allergology and Clinical Immunology II Gaia Mancuso, Locarno; Lara Šošić, Zürich
	SC41 Sequential administration of an mRNA-based seasonal influenza vaccine in older adults Nike Kräutler, Basel
	SC42 Microcrystalline tyrosine as a novel depot-forming agent in venom immunotherapy: a pre-clinical evaluation in bee-venom allergic mice Marta Paolucci, Zürich
	SC43 Improvement of Mixed Inflammatory Environment in Nasal Secretions of Diffuse Type 2 Chronic Rhinosinusitis with Nasal Polyps under Dupilumab Fabio Simon Ryser, Bern
	SC44 Fine-needle aspiration and CyTOF immune profiling of lymph nodes after grass pollen allergen intralymphatic immunotherapy: a randomized pilot trial Pål Johansen, Zürich

PROGRAMME – FRIDAY, 28 AUGUST 2026

	SC45 Phenotype-Tailored Prophylactic Immunomodulation Enables Safe Immune Checkpoint Inhibitor Rechallenge After Severe irAEs in High-Risk Patients Lucrezia Mencarelli, Lausanne
	SC46 When the Tonic turns Toxic: a delayed Type Allergy to Tonic Water Joana Lanz, St. Gallen
	SC47 Autoantibody-Based Stratification of Extraglandular Manifestation Risk in Sjögren's Disease Geoffrey Urbanski, Genève
	SC48 Cat-allergen intralymphatic immunotherapy: results of the single-dose escalation phase from the ongoing CAT-ILIT study Pål Johansen, Zürich
Sala E	YSIS Session Mariana Borsa, Basel; Ursula Karolin Düren, Basel
	SC49 Polysorbate 80 Impairs Gut Barrier and Drives Systemic Inflammation via PPARα-Mediated Fatty Acid Oxidation and Mitochondrial Dysfunction Can Zeyneloglu, Davos Wolfgang
	SC50 An unconventional cyclin regulates cysteinyl leukotriene release from tuft cells during parasite infections Pascal Flüchter, Zürich
	SC51 Cross-reactive Peptides: A Mechanistic Link Between Multiple Sclerosis and Epstein-Barr Virus Philipp Nawrath, Bellinzona
	SC52 Investigation of the role of IL-33 for intestinal tumorigenesis Anja Herbst, Bern
	SC53 Biomarkers in Sarcoidosis: an Inflammatory Perspective Roberto Colli, Zürich
10:30 - 11:00	Coffee Break

Flexible, up to once monthly* facilitated subcutaneous immunoglobulin for PID and SID¹

- **Personalized administration**¹
Flexible infusion intervals (up to once monthly)¹
- **Proven efficacy**²⁻⁵
Reduction in infection rates similar to IVIG^{2,4}
- **Well-documented tolerability**^{2,3,6}
Most adverse events were mild to moderate^{2,3,6-8}



NOW AVAILABLE AS PRE-FILLED PEN⁹



- **Ready-to-use**⁹
single dose in a pre-filled pen
- **Automatic**^{9,10}
injection process with two signals (visual and audio)
- **User-friendly**⁹
application with a hidden and retractable needle

FLEXIBLE & INDIVIDUALIZED LONG-TERM PROPHYLAXIS FOR HAE⁹

HyQvia® is indicated for primary immunodeficiency syndromes (PID) with impaired antibody production and secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)** or serum IgG level of <4 g/L.¹

TAKHZYRO® is indicated for the long-term prophylaxis of hereditary angioedema (HAE) attacks in patients aged 2 years and older. The TAKHZYRO® 300 mg pre-filled pen is indicated for adults and adolescents aged 12 years and older.⁹

HAE: hereditary angioedema; **IgG:** immunoglobulin G; **IVIG:** intravenous immunoglobulin; **PID:** primary immunodeficiency; **PSAF:** proven specific antibody failure; **SID:** secondary immunodeficiency.

* In PID patients naive to immunoglobulin therapy, the HyQvia® dose required to achieve a trough IgG level of 6 g/L is of the order of 0.4 to 0.8 g/kg body weight per month. The dose interval to maintain steady-state levels varies from 2- to 4-weeks. For PID patients previously treated with immunoglobulin, treatment can be adjusted to a 3- or 4-weeks interval. The recommended dose of HyQvia® for SID is 0.2 to 0.4 g/kg every 3 to 4 weeks.¹

**PSAF: failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines.¹

References: 1. HyQvia® Prescribing information: www.swissmedicinfo-pro.ch. 2. Dimou M, et al. Efficacy-safety of facilitated subcutaneous immunoglobulin in immunodeficiency due to hematological malignancies. A single-center retrospective analysis. *Anticancer Res.* 2018; 38, 4187-4191. 3. Dimou M, et al. Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis. *Cancers (Basel).* 2023;15(18):4524. 4. Gungoren EY, et al. Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort. *J Clin Immunol.* 2024;44(8):169. 5. Wiesik-Szewczyk E, et al. Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies. *Front Immunol.* 2020;11:981. 6. Patel NC, et al. Facilitated Subcutaneous Immunoglobulin 10% Safety Among Pediatric Patients With Primary Immunodeficiency Diseases. *J Allergy Clin Immunol Pract.* 2025;13(10):2590-2599. 7. Ellerbroek PM, et al. Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study. *Immunotherapy.* 2024;16(10):679-691. 8. Rubinstein A, et al. Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study. *J Clin Immunol.* 2024;44(8):181. 9. TAKHZYRO® 300 mg Prescribing information: www.swissmedicinfo-pro.ch. 10. TAKHZYRO® 300 mg Patient information: www.swissmedicinfo.ch. Healthcare professionals may request a complete copy of the cited literature from the pharmaceutical company.

C-APROM/CH/HYQ/0133_05/2026

PROGRAMME – FRIDAY, 28 AUGUST 2026

11:00 – 12:30

SSAI-AILD Parallel Sessions

Sala B3

Drug Related Immunological Reactions

Andreas Bircher, Lugano; Stephan Krähenbühl, Basel

DILI, Possible Mechanism and Identifying the Causal Drug

Werner Pichler, Bern

Drug-induced autoimmune-like hepatitis: Challenges in diagnosis and treatment

Guido Stirnimann, Bern

JAK inhibitors in clinical immunology: Benefits and possible adverse events from a rheumatological perspective

Jérôme Avouac, Paris FR

The Role of JAK Inhibitors in Autoimmune Liver Diseases

Carlo Selmi, Milano IT

Sala B1

Cancer and Immunity

Arianna Calcinotto, Bellinzona; Benedetta Terziroli Beretta-Piccoli, Lugano

Exploring Kupffer Cell-mediated priming for anti-HCC immunity and beyond

Ping-Chih Ho, Epalinges

Immune Mechanisms Controlling Leukemic Stem Cells

Adrian Ochsenbein, Bern

Distinct pathobionts driving inflammatory bowel disease and precision therapy approaches

Lukas Mager, Tübingen DE

Sala C

Clinical Allergology

Silvy Bach Bizzozero, Giubiasco; Milena Sokolowska, Zürich

Recongnition and management of severe food allergies

Alessandro Fiocchi, Roma IT

Drug allergies

Thomas Harr, Genève

Pollen-Food Allergies

Barbara Ballmer-Weber, St. Gallen

Sala E

Diagnostic

Luca Bernasconi, Aarau; Alessia Palumbo, Bellinzona

Autoantibodies in Glomerulonephritis: From Mechanisms to Clinical Impact

Renato Alberto Sinico, Milano IT

What's New in the ICAP Classification Tree

Maria Infantino, Firenze IT

Pathogenic autoantibodies in neurological diseases

Christian Moritz, Saint-Priest-en-Jarez FR

12:30 – 13:45

Lunch break



Succinct Statement
TAKHZYRO

takeda.info/ch_KFI_Takhzyro



Succinct Statement
HyQvia

takeda.info/HyQvia_KFI

AWARDS

Brunello Wüthrich Award

The Brunello Wüthrich – aha! Neurodermitis (Atopic dermatitis) Research Prize for the **BEST POSTER PRESENTATION ON EPIDEMIOLOGICAL, CLINICAL OR IMMUNOLOGICAL RESEARCH IN ATOPIC DERMATITIS** (amount of CHF 1'000.–)



Acteria

Fondation ACTERIA offers one CHF 1'000.– award for the best oral presentation each on the following topics during the Annual Congress of the SSAI: Allergology | Clinical Immunology | Basic Immunology | Translational Science



Biotest (Schweiz) AG Awards

«SCIENCE MEETS QUALITY»

Three Biotest Awards, each valued at CHF 1'000.–, will be presented for the best posters in the categories of «Basic Immunology», «Clinical Immunology» and «Allergology/Allergy or Translational Science».



SYIS – Best oral presentation Award

The Swiss Young Immunologists Society (SYIS) offers one award for the best oral presentation among its members



Swiss Autoimmune Liver Disease Award 2026

Fondazione Epatocentro Ticino in collaboration with industry sponsors offers two awards, each valued with CHF 500.–. They will be awarded to the

BEST POSTER AND THE BEST ORAL PRESENTATION IN THE FIELD OF AILD

selected by the scientific committee.



Gilead Science Switzerland Award

The Gilead Science Switzerland Award Research Prize will be awarded for the best Poster on Autoimmune Liver Disease Research (amount of CHF 500.–)



PROGRAMME – FRIDAY, 28 AUGUST 2026

12:45 – 13:30

Sala B2

Guided poster tour II

Arianna Calcinotto, Bellinzona/Lugano; Davide Robbiani, Bellinzona/Lugano; Johannes Trück, Zürich; Thomas Hauser, Zürich

CI09 Invasive maxillary sinus pseudotumor as a rare manifestation of IgG4-related disease: two case reports

Gabriel Bronz, Lausanne

CI07 Tofacitinib in the Treatment of Cardiac Sarcoidosis: Towards Steroid-Sparing Disease Management

Melina Stüssi-Helbling, Zürich

CI05 Systemic inflammatory markers define the biological response to wildfire smoke exposure

Huseyn Babayev, Davos Wolfgang

TS07 Lack of porcine MHC-I rules over hPD-L1-mediated regulation of human xenogeneic cytotoxic CD8 T cell responses

Viktoriia Galdina, Genève

CI11 Integrated Barrier and Multi-Omic Analysis Identifies Molecular Signatures of Response to Tralokinumab in Atopic Dermatitis

Can Zeyneloglu, Davos Wolfgang

BI07 Inborn errors of immunity promote a spectrum of gain-of-survival states of lymphocytes with autoreactive properties

Christoph Schultheiss, Basel

12:45 – 13:30

Industry Symposium

Sala B1

Navigating cross-reactivity and immune response in modern AIT: Interactive workshop

Milena Sokolowska, Davos;
Peter Schmid-Grendelmeier, Zürich;
Oliver Fuchs, Luzern



Sala B3

Entering a NEW ERA of HAE Care: Clinical Cases Highlighting Oral Treatment Strategies

Isabel Morales, Luzern;
Petra Staubach-Renz, Mainz DE



13:45 – 14:15

Sala A

Award Ceremony

WE SEE
A PROTECTED
LIFE IN
EVERY LIFE

Our plasma-derived
therapies support
our patients to lead
better lives.



HEMOPHILIA | IMMUNOLOGY | TRANSPLANTATION | INTENSIVE CARE

WE SEE
A SECOND
LIFE IN
EVERY LIFE

Our plasma-derived
therapies support
our patients to lead
better lives.



Biotest

From Nature for Life

PROGRAMME – FRIDAY, 28 AUGUST 2026

14:15 – 15:15

Sala A

Plenary 3

Senescence and Immunity: Autoimmunity in the Elderly and Immune Dysfunction

Roger Geiger, Bellinzona; Michael Heneghan, London GB

Immune ageing and dysfunction as a driver of senescence

Christina Camell, Minneapolis US

Senescence and Immunity in Aging and Cancer

Andrea Alimonti, Bellinzona

15:15 – 16:15

Sala A

Plenary 4

Clinically Relevant Primary Immune Deficiencies (PID): What Is New?

Peter Jandus, Genève; Christiane Sokollik, Bern

Mosaic errors of immunity: diagnostic challenges and targeted therapeutic options

Mike Recher, Basel

The conundrum of paediatric autoimmune liver disease and immunodeficiency.

Marianne Samyn, London GB

16:15 – 16:30


Sala A

Closing Ceremony SSAI/AILD

Andreas Cerny, Lugano; Greta Guarda, Bellinzona;

Burkhard Ludewig, St. Gallen

EXHIBITION PLAN



SPONSORS AND EXHIBITORS

Gold sponsors

19

NOVARTIS

Novartis Pharma Schweiz AG, Rotkreuz

20

GSK

GlaxoSmithKline AG, Münchenbuchsee

Silversponsors

07

Takeda

Takeda Pharma AG, Glattpark

22

Biotest
From Nature for Life

Biotest (Schweiz) AG, Ruppertswil

Bronzesponsors

16

CSL Behring

CSL Behring AG, Bern

28

CELLTRION iQONE

iQone Healthcare Switzerland
(a Celltrion Company), Versoix

12

ALK

ALK-Abelló AG, Wallisellen

Exhibitors

05	RUWAG Handels AG, Bettlach	04
12	Sanofi-Regeneron, Vernier	34
17	Sebia Swiss GmbH, Wollerau	08
31	Association Research for Life, Zürich	
AstraZeneca AG, Baar		06
Beckman Coulter Life Sciences, Nyon		11
Bencard AG, Greifensee		13
Biotest (Schweiz) AG, Ruppertswil		07
Careformance GmbH, Eschlikon		25
CSL Behring AG, Bern		29
Euroimmun Schweiz AG, Kriens		
Gilead Sciences Switzerland Sàrl, Zug		
GlaxoSmithKline AG, Münchenbuchsee		
iQone Healthcare Switzerland (a Celltrion Company), Versoix		
KalVista Pharmaceuticals Switzerland GmbH, Zug		
MediService AG, Zuchwil		
Moderna Switzerland GmbH, Basel		
Novartis Pharma Schweiz AG, Rotkreuz		
Octapharma AG, Lachen		
Otsuka Pharmaceutical (Switzerland) GmbH, Glattbrugg		
01	Sonic Suisse SA, Niederwangen	
02	Stallergenes Greer, Dietlikon	
03	Takeda Pharma AG, Glattpark-Opfikon	
06	Thermo Fisher Diagnostics AG, Reinach	
08	Waters Biosciences, Eysins	
10		
11		
13		
14		
15		
18		
20		
21		
23		
24		
26		
27		
29		
30		
32		
33		
35		
36		

Additional Support

05	BioCryst Schweiz GmbH, Zug
06	Careformance GmbH, Eschlikon
07	Clinica Luganese/Santa Chiara, Lugano
08	Ipsen Pharma Schweiz GmbH, Zug
09	iQone Healthcare Switzerland (a Celltrion Company), Versoix
10	KalVista Pharmaceuticals Switzerland GmbH, Zug
11	Otsuka Pharmaceutical (Switzerland) GmbH, Glattbrugg
12	Stallergenes Greer, Dietlikon

SSP/SSTS-SSAI

Joint Annual Meeting 2027

30 June – 02 July 2027, St. Gallen

— ■ *Save the Date*

Joint Annual Meeting

Swiss Society of Pneumology (SSP)
Swiss Society for Allergy and Immunology (SSAI)
Swiss Society for Thoracic Surgery (STS)

Partner Societies

Swiss Society of Pediatric Pneumology (SSPP)
Swiss Society for Pulmonary Hypertension (SSPH)



www.pneumo-congress.ch



OLMA MESSEN

GENERAL INFORMATION

Venue

Palazzo dei Congressi Lugano
Piazza Indipendenza 4, 6900 Lugano

Congress language

English (no simultaneous translation)

Registration fee

	1 day pass	2 day pass
SSAI-Member / SASL-Member	CHF 300.00	CHF 450.00
Non-members	CHF 350.00	CHF 500.00
Assistant/Student/Nurse	CHF 150.00	CHF 250.00
Patient	CHF 0.00	CHF 0.00

Administrative Organisation

Medworld AG

Ms. Andrea Studer
Ms. Nejla Dzaferi

Sennweidstrasse 46, 6312 Steinhausen
Phone: +41 41 748 23 00
E-Mail: registration@medworld.ch
> www.medworld.ch

Booth No. 14

- Personalized training** for patients and caregivers.
- Available 24/7** in any emergency.
- Support with **cost approval** and prescriptions processing.
- High-quality care** for your patients.
- Free home delivery** of medication and infusion materials.

Bigger than allergies

Defy respiratory allergy with the help of a sublingual allergy immunotherapy¹

ACARIZAX®

GRAZAX®

ITULAZAX®

The SLIT-portfolio
is approved for
children aged 5
and older^{1,2}

Reference: 1. See the currently approved information for healthcare professionals for ACARIZAX®, Grazax® and ITULAZAX® at www.swissmedicinfo-pro.ch or listed below.
2. See www.spezialistenliste.ch.

Abridged Information for healthcare professionals ACARIZAX®, GRAZAX®, ITULAZAX®. **Comp.** Hyposensitised allergen extract tablets for specific immunotherapy. Each sublingual tablet contains: ACARIZAX® 12 SQ-HDM (Acari allergeni extractum normatum (Dermatophagoides pteronyssinus, Dermatophagoides farinaceus)), GRAZAX® 75,000 SQ-T (Pollinis allergeni extractum normatum (Pleum pratense)), ITULAZAX® 12 SQ-BET (Pollinis allergeni extractum normatum (Betula verrucosa)). **Excipients:** gelatin (from fish), mannitol, sodium hydroxide q.s., corresponding to up to 0.5 mg sodium. **I/U:** Treatment only with a positive history, positive skin prick test and / or positive specific IgE test to the relevant allergen. **ACARIZAX®:** Children and adults (5-65 years); treatment of moderate to severe allergic rhinitis induced by house dust mites. **GRAZAX®:** Adults and children from the age of 5 years; treatment of grass pollen-induced rhinitis and conjunctivitis. **ITULAZAX®:** Adults and children from the age of 5 years; treatment of moderate to severe allergic rhinitis and / or conjunctivitis induced by pollen from the birch homologous group of trees. **D:** 1 tablet once a day under the tongue. The first dose must be taken under medical supervision. Severe allergic reactions may also occur later during the course of treatment. **CI:** Hypersensitivity to any of the excipients. Patients with an FEV₁ < 70% of the predicted value at the start of treatment. Severe asthma exacerbation in the last three months. Active or poorly controlled autoimmune disorders, immune defects, immunodeficiencies, immunosuppression or malignant neoplastic diseases. Severe and / or unstable asthma. Severe oral inflammation or wounds in the mouth. Acute infection of the respiratory tract. Confirmed diagnosis and active symptoms of eosinophilic oesophagitis. **W/P:** Asthma is a known risk factor for severe systemic allergic reactions. In the event of severe systemic allergic reactions, treatment must be discontinued and a physician contacted immediately. Anaphylactic reactions should primarily be treated with adrenaline, although interactions with other drugs may occur (e.g., beta-blockers, tricyclic anti-depressants, MAO inhibitors and / or COMT inhibitors). Isolated cases of eosinophilic oesophagitis have been reported. **IA:** Concomitant treatment with symptomatic anti-allergy drugs may increase the patient's tolerance level. **P/L:** Treatment should not be initiated during pregnancy or lactation. **EADOM:** No corresponding studies have been performed. **UE:** Mild to moderate, mostly transient local reactions are to be expected (e.g., irritation of the mouth and throat, pruritus, swelling, headache, malaise). Severe local allergic reactions and even anaphylaxis may occur. **O:** Doses higher than the recommended daily dose increase the risk of adverse reactions and severe allergic reactions. These reactions should be treated with appropriate symptomatic drugs. **P:** ACARIZAX®: 30, 90 tablets. GRAZAX®: 30, 100 tablets. ITULAZAX®: 30, 90 tablets. **Dispensing category:** A. **Revision of the text:** ACARIZAX® 01-2026, GRAZAX® 07-2025, ITULAZAX® 07-2025. **See current information for healthcare professionals at** www.swissmedicinfo-pro.ch. ALK-Abello AG, Richtstrasse 11, 8304 Wallisellen, Switzerland, phone +41 44 908 21 00, www.alk.net/ch

Healthcare professionals can request all references from ALK-Abello AG.